Sargent Bickham Lagudis LLC Outlook Therapeutics, Inc. Transaction History

Sargent Bickham Lagudis LLC

  • $1.22 Billion
  • Q4 2022

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 27, 2022
SELL
$1.22 - $2.03 $1,220 - $2,029
-1,000 Closed
0 $0
Q4 2021

Jan 18, 2022
BUY
$1.27 - $2.23 $1,270 - $2,230
1,000 New
1,000 $1,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $332M
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email